EUVIMEDEUVIMED entdecken
Systematische ÜbersichtÜbersichtsarbeit

Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients

Parul Berry, Raseen Tariq, Darrell S Pardi, Sahil Khanna

Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 949-973

DOI: 10.1016/j.cgh.2025.06.043 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Parul Berry und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Immunocompromised Host, Clostridium Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Takeda Pharmaceutical Company, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Clostridioides difficile infection (CDI) poses a significant health risk to immunocompromised hosts due to the increased risk of severe infection and recurrence. Microbiota-based therapies have emerged as a promising strategy for CDI, but safety and efficacy in immunocompromised populations remain underexplored. METHODS: A comprehensive literature search across Ovid MEDLINE, Ovid EMBASE, Clinicaltrials.gov, and Scopus from inception until December 16, 2024, identified studies meeting inclusion criteria, covering fecal microbiota transplantation (FMT) for recurrent CDI (rCDI) in immunocompromised individuals, including those on immunosuppressants, transplant recipients, undergoing chemotherapy, and with advanced HIV. Case reports and studies not separately reporting outcomes in immunocompromised patients were excluded. Statistical analysis was performed using random-effects models to account for heterogeneity among studies. RESULTS: A total of 44 studies (31 full-text articles, 13 abstracts) were included, comprising 3476 participants, of whom 1208 were immunocompromised. The population included solid organ transplant recipients (n = 219), patients with cancer on chemotherapy (n = 101), hematopoietic stem cell transplant recipients (n = 29), and advanced HIV patients (n = 11). The most common FMT route was colonoscopy (n = 12 studies), followed by upper gastrointestinal routes, capsules, and rectal retention enemas. The clinical resolution rate after a single FMT was 75.3% (95% confidence interval [CI], 71.7%-78.6%), increasing to 87.4% (95% CI, 84.8%-89.6%) with consecutive treatments. The recurrence rate was 23.9% (95% CI, 19.2%-29.4%), and the serious adverse event rate was 10.1% (95% CI, 6.7%-14.8%). CONCLUSIONS: The safety and effectiveness outcomes of FMT in mild to moderately immunocompromised populations for rCDI are comparable to those in immunocompetent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationImmunocompromised HostClostridium InfectionsHumansClostridioides difficileRecurrenceTreatment Outcome

Stichwörter der Autor:innen

Clostridioides difficile InfectionFecal Microbiota TransplantationImmunocompromised HostsMeta-analysis

Autor:innen und Institutionen

  • Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: khanna.sahil@mayo.edu.

Förderung

  • Takeda Pharmaceutical Company
  • Pfizer

Zitieren

APA

Berry, P., Tariq, R., Pardi, D. S., & Khanna, S. (2026). Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients. Clinical Gastroenterology and Hepatology, 24(4), 949-973. https://doi.org/10.1016/j.cgh.2025.06.043

Vancouver

Berry P, Tariq R, Pardi DS, Khanna S. Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients. Clinical Gastroenterology and Hepatology. 2026;24(4):949-973. doi:10.1016/j.cgh.2025.06.043

BibTeX
@article{Berry2026,
  author = {Berry, Parul and Tariq, Raseen and Pardi, Darrell S and Khanna, Sahil},
  title = {Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {949--973},
  doi = {10.1016/j.cgh.2025.06.043}
}
Kostenlos starten →